Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 6/20 | 0.69 |
| ▸ | CAMKK2 | Q96RR4 | 5/20 | 0.66 |
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.52 |
| ▸ | SGK1 | O00141 | 1/20 | 0.52 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8255005 | 0.91 | CAMKK2 (0.74) | AXLCAMKK2SGK1AAK1IGF1R | |
| SCHEMBL11929261 | 0.84 | CAMKK2 (0.60) | AXLCAMKK2SGK1AAK1IGF1R | |
| SCHEMBL8320208 | 0.81 | CAMKK2 (0.67) | CAMKK2AAK1 | |
| SCHEMBL15161540 | 0.81 | CAMKK2 (0.61) | AXLCAMKK2NEK1SGK1AAK1 | |
| SCHEMBL1487600 | 0.80 | CAMKK2 (0.79) | AXLCAMKK2AAK1IGF1R | |
| SCHEMBL13745445 | 0.80 | CAMKK2 (1.00) | AXLCAMKK2NEK1SGK1IGF1R | |
| SCHEMBL1487961 | 0.79 | CAMKK2 (0.67) | AXLCAMKK2SGK1AAK1IGF1R | |
| SCHEMBL11924769 | 0.79 | CAMKK2 (0.62) | AXLCAMKK2SGK1AAK1IGF1R | |
| SCHEMBL13753981 | 0.79 | CAMKK2 (0.74) | AXLCAMKK2SGK1AAK1IGF1R | |
| SCHEMBL8321116 | 0.79 | CAMKK2 (0.74) | CAMKK2AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142366-A1 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142366-A1 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | API5, MAP3K5, MAP3K7 | AXL 2132/4885CAMKK2 83/4885NEK1 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.